

Date

Deadline

CONTACT

Organisation	ISTITUTO SUPERIORE DI SANITA PIC 999978821 VAT IT03657731000	Department	Oncology and Molecular Medicine
Contact person	Desiree Bonci	Email	desiree.bonci@iss.it
City	Rome	Website	www.iss.it
Country	Italy		

Organisation type

Research organisation type	<input checked="" type="checkbox"/> Research Organisation	Is your company a Small and Medium Sized Enterprise (SME*)? Number of employees:	<input type="checkbox"/> YES x <input type="checkbox"/> NO
	<input type="checkbox"/> University		
	<input type="checkbox"/> Company		
	<input type="checkbox"/> Other		

Your enterprise is an SME if:

- it is engaged in **economic activity**
- it has **less than 250 employees**
- it has either an **annual turnover not exceeding €50M**, or an **balance sheet total not exceeding €43M**
- it is **autonomous**

For the definition of SMEs, look at: http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

Short introduction of key areas of institute's research:

Oncology and translational medicine

Former participation in an FP European project?

☒ YES ☐ NO

Project title / Acronym:

Prolipsy- Early detection of prostate cancer (PCa) by liquid biopsies (Transca-2- (Project funded under JTC 2016).

Activities performed:

The primary aim of this research proposal is to improve blood-based detection of PCa patients by testing of circulating tumor cells (CTCs), tumour-derived exosomes and circulating cell-free DNA (cfDNA) as Liquid biopsies.

Expertise / Commitment offered

Description of your expertise:

Proposal data:

Acronym: MISTYC

MISTYC-An innovative non-invasive approach combining Multiple types of bio-indicators by Immuno-Seq Technology: from the microbiome to Cancer.

Biomarker discovery can drive an exact diagnosis and staging of the tumors. Cancers release nanovesicles into fluids. Vesicle molecular cargo analysis represents a new way of disclosing cancer heterogeneity (Cannistraci. A Oncogene. 2017; Signore M.et al.CDD.2021). Our expertise and research activity is focused on optimizing tools and studying the diagnostic and prognostic potentiality of bacteria-RNA, new non-coding RNA sets (i.e Pyknons, IsomiR, T-RF-t-RNA, RNAY, etc.), DNA mutations, and proteomic profiles as non-invasive-vesicle-based monitoring of cancer heterogeneity, progression, and microbiome role in patients by new proteomic and NGS approaches.

ISTITUTO SUPERIORE DI SANITA PIC 999978821 VAT
IT03657731000 (www.iss.it)

Keywords specifying
your expertise:

Biomarkers and cancer monitoring

Commitment offered:

☒ Research ☐ Demonstration ☐ Training
☒ Technology ☐ Dissemination ☐ Other:

Interested in
participation in
project types:

<input checked="" type="checkbox"/> Research & Innovation Action	<input type="checkbox"/> Innovation Action	<input type="checkbox"/> EIC Pathfinder
--	--	---

Work Programme research areas: indicate your interest

Horizon Europe Framework Programme (HORIZON)

Call topic(s):

Develop new methods and technologies for cancer screening and early detection
HORIZON-MISS-2021-CANCER-02-01

Do you have other
partners for this
topic (which
partners/country)?

no

Profile of partner sought

Role

<input checked="" type="checkbox"/> technology development	<input checked="" type="checkbox"/> research	<input type="checkbox"/> training
<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____

Country /region

<input type="checkbox"/>

Expertise required

<p>We are looking for partners with experts in biomarker development who have an interest in developing a rapid diagnostic test.</p>
--

I agree with the publication of my contact data: ☒ YES ☐ NO